AQUESTIVE THERAPEUTICS INCAQST
ASignal's systematic analysis rates AQST as Bullish.
Reflects the latest available analysis · analyzed Sep 30, 2026
The case on AQST
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (38.1% YoY)
- High gross margin (67.04%) indicating pricing power
- Solid current and quick ratios (7.19x and 6.54x) suggesting strong liquidity
- Positive free cash flow trend expected as company scales
- Low debt with high cash balance ($98.49M cash vs $59.03M debt)
- Negative operating and net margins (-59.51% and -144.63%)
- Negative free cash flow (-$26.89M)
- Overvalued metrics: high EV/Revenue (10.11x), negative EV/EBITDA (-10.47x)
- MACD bearish crossover with negative histogram
- Price below 20-day and 50-day moving averages (SMA20: 4.899, SMA50: 4.532)
- No Reddit mentions indicating low retail investor interest
See the full verdict on AQST
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AQST
Most investors never get a second opinion, let alone several. ASignal runs AQST past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.